Scinai Immunotherapeutics Ltd. (SCNI) stock
SCNINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.37−0.03 (-7.82%)
Close on Nov 17, 2026Market cap $1.29MP/E –Yield –
Scinai Immunotherapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
For fiscal 2025 it was -$6.12M. The highest annual figure on record is -$6.12M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$6.12M | – |
| FY2024 | Dec 31, 2024 | -$6.99M | – |
| FY2023 | Dec 31, 2023 | -$9.19M | – |
| FY2022 | Dec 31, 2022 | -$10.50M | – |
| FY2021 | Dec 31, 2021 | -$10.39M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2023 | Jun 30, 2023 | -$2.45M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.05M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.12M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.48M | – |
See a number that looks wrong?